• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Inozyme Pharma Inc. (Amendment)

    2/14/24 6:08:47 PM ET
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INZY alert in real time by email
    SC 13G/A 1 nea-sch13g_18798.htm NEW ENTERPRISE ASSOCIATES 15, L.P. / INOZYME PHARMA -- 13G/A(#2E)

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

      

     

     

    Inozyme Pharma, Inc.

    (Name of Issuer)

       

    Common stock, $0.0001 par value per share

     

    (Title of Class of Securities)

      

    45790W108

     

    (CUSIP Number)

      

    December 31, 2023

     

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☒   Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No.  45790W108

    13G Page 2 of 9 Pages    

     

     

    Item 1(a). Name of Issuer:

     

    Inozyme Pharma, Inc. (the “Issuer”).

     

     

    Item 1(b). Address of Issuer's Principal Executive Offices:

     

    321 Summer Street, Suite 400, Boston, Massachusetts 02210.

     

     

    Item 2(a). Names of Persons Filing:

     

    This statement is being filed by New Enterprise Associates 15, L.P. (“NEA 15”); NEA Partners 15, L.P. (“NEA Partners 15”), which is the sole general partner of NEA 15; NEA 15 GP, LLC (“NEA 15 GP”), which is the sole general partner of NEA Partners 15; and Forest Baskett (“Baskett”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Scott D. Sandell (“Sandell”) and Peter W. Sonsini (“Sonsini”) (collectively, the “Managers”). The Managers are the managers of NEA 15 GP. NEA 15, NEA Partners 15, NEA 15 GP and the Managers are sometimes referred to collectively herein as the “Reporting Persons”. 

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The address of the principal business office of NEA 15, NEA Partners 15, NEA 15 GP and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Makhzoumi, and Sonsini is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001.

     

     

    Item 2(c). Citizenship:

     

    Each of NEA 15 and NEA Partners 15 is a Delaware limited partnership. NEA 15 GP is a Delaware limited liability company. Each of the Managers is a United States citizen.

     

     

    Item 2(d). Title of Class of Securities:

     

    Common stock, $0.0001 par value (“Common Stock”).

     

     

    Item 2(e). CUSIP Number:

     

    45790W108

     

      

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     
     

    CUSIP No.  45790W108

    13G Page 3 of 9 Pages    

     

    Item 4. Ownership:

     

    Not applicable.

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

    Each Reporting Person has ceased to beneficially own five percent (5%) or more of the Issuer’s outstanding Common Stock.

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable. The Reporting Persons expressly disclaim membership in a “group” as used in Rule 13d-5(b).

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

    Item 10. Certification.

     

    Not applicable. This Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d–1(c).

     

     

    Material to be Filed as Exhibits.

     

    Exhibit 1 – Agreement regarding filing of joint Schedule 13G.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     
     

    CUSIP No.  45790W108

    13G Page 4 of 9 Pages    

     

     

    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 14th day of February, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:NEA PARTNERS 15, L.P.
    General Partner

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                       *                      

      Scott D. Sandell

      Chief Executive Officer

     

     

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                        *                      

     Scott D. Sandell

     Chief Executive Officer

     

     

      

    NEA 15 GP, LLC

     

    By:                        *                      

     Scott D. Sandell

     Chief Executive Officer

     

     

     

                                  *                       

    Forest Baskett

     

     

                                  *                        

    Anthony A. Florence, Jr.

     

     

                                  *                       

    Mohamad H. Makhzoumi

     

     

                                  *                       

    Joshua Makower

     

     

     

     

     

     

    CUSIP No.  45790W108

    13G Page 5 of 9 Pages    

      

     

     

     

     

                                  *                       

    Scott D. Sandell

     

     

                                  *                       

    Peter W. Sonsini

     

     

     

    */s/ Stephanie Brecher             

    Stephanie Brecher

    As attorney-in-fact

     

    This Amendment No. 2 to Schedule 13G was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

    CUSIP No.  45790W108

    13G Page 6 of 9 Pages    

     

     

    Exhibit 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Inozyme Pharma, Inc.

     

    EXECUTED this 14th day of February, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:NEA PARTNERS 15, L.P.
    General Partner

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                       *                      

      Scott D. Sandell

      Chief Executive Officer

     

     

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:                        *                      

     Scott D. Sandell

     Chief Executive Officer

     

     

      

    NEA 15 GP, LLC

     

    By:                        *                      

     Scott D. Sandell

     Chief Executive Officer

     

     

     

                                  *                       

    Forest Baskett

     

     

                                  *                        

    Anthony A. Florence, Jr.

     

     

                                  *                       

    Mohamad H. Makhzoumi

     

     

                                  *                       

    Joshua Makower

     

     

     

     

     

     

     

    CUSIP No.  45790W108

    13G Page 7 of 9 Pages    

     

     

     

     

                                  *                       

    Scott D. Sandell

     

     

                                  *                       

    Peter W. Sonsini

     

     

     

    */s/ Stephanie Brecher             

    Stephanie Brecher

    As attorney-in-fact

     

    This Agreement was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

    CUSIP No.  45790W108

    13G Page 8 of 9 Pages    

    Exhibit 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett                    

    M. James Barrett

     

    /s/ Peter J. Barris                            

    Peter J. Barris

     

    /s/ Forest Baskett                         

    Forest Baskett

     

    /s/ Ali Behbahani                         

    Ali Behbahani

     

    /s/ Colin Bryant                            

    Colin Bryant

     

    /s/ Carmen Chang                        

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.      

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher                  

    Carol G. Gallagher

     

    /s/ Dayna Grayson                       

    Dayna Grayson

     

    /s/ Patrick J. Kerins                      

    Patrick J. Kerins

     

     

     

     

     

     

     

     

     

      

    CUSIP No.  45790W108

    13G Page 9 of 9 Pages    

     

     

     

    /s/ P. Justin Klein                         

    P. Justin Klein

     

    /s/ Vanessa Larco                        

    Vanessa Larco

     

    /s/ Joshua Makower                    

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi    

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers                

    Edward T. Mathers

     

    /s/ David M. Mott                        

    David M. Mott

     

    /s/ Sara M. Nayeem                     

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                        

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos         

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta                 

    Chetan Puttagunta

     

    /s/ Jon Sakoda                              

    Jon Sakoda

     

    /s/ Scott D. Sandell                      

    Scott D. Sandell

     

    /s/ A. Brooke Seawell                 

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini                     

    Peter W. Sonsini

     

    /s/ Melissa Taunton                    

    Melissa Taunton

     

    /s/ Frank M. Torti                        

    Frank M. Torti

     

    /s/ Ravi Viswanathan                  

    Ravi Viswanathan

     

    /s/ Paul E. Walker                         

    Paul E. Walker

     

    /s/ Rick Yang                                

    Rick Yang

     

     

     

     

     

     

    Get the next $INZY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INZY

    DatePrice TargetRatingAnalyst
    12/12/2024$26.00Outperform
    Raymond James
    9/12/2024$16.00Buy
    Stifel
    8/13/2024$16.00 → $17.00Buy
    Jefferies
    5/30/2024$14.00Overweight
    Wells Fargo
    3/23/2023$4.50 → $6.00Hold → Buy
    Jefferies
    5/26/2022$5.00Hold
    Jefferies
    2/7/2022$33.00Buy
    HC Wainwright & Co.
    11/29/2021$23.00Buy
    Needham
    More analyst ratings

    $INZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Inozyme Pharma with a new price target

      Raymond James initiated coverage of Inozyme Pharma with a rating of Outperform and set a new price target of $26.00

      12/12/24 8:10:19 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Inozyme Pharma with a new price target

      Stifel initiated coverage of Inozyme Pharma with a rating of Buy and set a new price target of $16.00

      9/12/24 7:42:17 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Inozyme Pharma with a new price target

      Jefferies resumed coverage of Inozyme Pharma with a rating of Buy and set a new price target of $17.00 from $16.00 previously

      8/13/24 7:33:31 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:16:07 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Winton Matthew closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:08:49 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bolte Axel closing all direct ownership in the company (SEC Form 4)

      4 - Inozyme Pharma, Inc. (0001693011) (Issuer)

      7/3/25 7:07:07 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    SEC Filings

    See more
    • SEC Form EFFECT filed by Inozyme Pharma Inc.

      EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)

      7/2/25 12:15:26 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Inozyme Pharma Inc.

      EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)

      7/2/25 12:15:16 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Inozyme Pharma Inc.

      25-NSE - Inozyme Pharma, Inc. (0001693011) (Subject)

      7/1/25 9:54:57 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

      BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the "Annual Meeting"), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the "Acquisition") by BioMarin Pharmaceutical Inc. ("BioMarin"). If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take such further action as it deems appropriate to call and convene the Annual Meeting at a later date, including the establishment of a new record date for determining the stockholders entitl

      6/20/25 5:00:00 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Financials

    Live finance-specific insights

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

      - Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - - Favorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing in ongoing and future clinical trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage

      4/8/24 6:30:35 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Leadership Updates

    Live Leadership Updates

    See more
    • Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

      - Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date - - ENERGY 3 trial on track for topline data in first quarter of 2026; no patient dropouts, dose adjustments or discontinuations, and no new safety signals - - Petra Duda, M.D., Ph.D. appointed Chief Medical Officer - BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financi

      5/14/25 7:30:00 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

      - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 - - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding - - Cash, cash equivalents, and short-term investments as of September 30, 2024, expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical c

      11/5/24 8:30:00 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

      BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry. "It is a privilege to welcome Erik to the Inozyme Board of Directors at this exciting juncture for Inozyme as we continue to lay the groundwork for ou

      10/7/24 8:30:17 AM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inozyme Pharma Inc.

      SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

      12/9/24 4:14:49 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inozyme Pharma Inc.

      SC 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)

      11/14/24 12:19:37 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Inozyme Pharma Inc.

      SC 13G - Inozyme Pharma, Inc. (0001693011) (Subject)

      10/24/24 2:02:10 PM ET
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care